HIV-1 VACCINE CANDIDATES DELIVERED BY VSV VECTORS
$2,740,852N01FY2010AINIH
Profectus Biosciences, Inc., Baltimore MD
Investigators
Abstract
Provide a research and administrative team that includes all expertise needed for the development, optimization, pre-clinical and clinical testing, and production of an HIV/AIDS vaccine based vesicular stomatitis virus (rVSV) as delivery tool of HIV vaccine immunogens
View original record on NIH RePORTER →